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Introduction
Pneumonia is an extremely common, yet exceedingly dangerous 
condition that makes up 423,000 emergency room visits and is 
the 8th leading cause of death in the United States, according to 
the CDC [1]. Inpatient community-acquired pneumonia (CAP) 
treatment is often empiric and laboratory testing may not result 
in a definite organism [2]. It has been demonstrated that the 
microbial etiology of roughly 30%-60% of CAPs treated in the 
inpatient setting remains unidentified [3-6]. Of those admitted 
to the hospital, 10-20% of patients are admitted to the ICU [7]. 
While imaging and prognosticating tools like the CURB-65 and 
Pneumonia Severity Index assist in the diagnosis and severity 
assessment of pneumonia, distinguishing between viral and 
bacterial pneumonia remains a challenge [8].
Bacterial pneumonia is a major cause of pathogen identified 
CAP. For example, Streptococcus pneumoniae is the most 
common cause of bacterial pneumonia, causing significant 
morbidity and mortality [7]. Tools like procalcitonin levels are 
helpful in the diagnosis and management of bacterial 
pneumonia [9]. On the other hand, viral pneumonia, a 
significant contributor to the prevalence of CAP, is identified 
by polymerase chain reaction (PCR) in more than 25% of 
cases using nasopharyngeal swabs and up to 40% when using 
lower respiratory tract samples [10]. Tools like rapid antigen 
testing and real time PCR assist in the diagnosis of several viral 
pneumonias [11]. Furthermore, morbidity and mortality of 
bacterial pneumonia after a preceding viral infection increases 
[12].
There is a large body of literature to help physicians identify, 
diagnose, treat, and manage CAP. Despite this, there is little data 
that directly compares the clinical syndromes and complications 
of bacterial pneumonia to viral pneumonia. Our study aims to 
compare the clinical presentation, morbidity and mortality of 
purely viral to purely bacterial etiologies of CAP.
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Abstract
Background: There exists a large body of literature to help identify, diagnose, treat, and manage 
community-acquired pneumonia (CAP). Despite this, there is little data that directly compares the 
clinical syndromes and complications of pure bacterial pneumonia to pure viral pneumonia. Our study 
compares the clinical presentation, morbidity and mortality of viral vs. bacterial etiologies of CAP.
Methods: This was a secondary data analysis of the Community-Acquired Pneumonia Organization 
(CAPO) international study database. Data was collected concerning patient demographics, physical 
examination findings, laboratory findings, radiological findings, severity of illness, and clinical 
outcomes and stratified according to the two study groups, CAVP and CABP. A microbiological 
diagnosis of CABP was based on the isolation of a bacterium from a respiratory sample, blood culture 
and/or identification of a urinary antigen for Streptococcus or Legionella; microbiological diagnosis 
of CAVP was based on polymerase chain reaction or antigen detection from respiratory samples.
Results: Our study included 1,913 patients. Of these, 286 (15.0%) had viral infection, while 1,627 
(85.0%) had CAVP. We found that bacterial CAP patients are older, more frequently male, and suffer 
from a higher proportion of comorbidities when compared to viral CAP patients. Comparison of 
physical exam findings and laboratory values failed to find a clinically significant difference between 
bacterial and viral CAP patients. When comparing severity of illness, bacterial CAP patients had 
greater frequency of PSI ≥ class IV; however, viral CAP patients more frequently needed ICU 
admission, ventilator support, vasopressor support, and had higher rate of in hospital mortality.
Conclusions: Our study confirms the extreme difficulty differentiating CABP from CAVP using 
demographics, physical exam, or x-ray findings. We found no major clinical or laboratory findings 
distinguishing CABP from CAVP. The increased severity of illness of CAVP compared to bacterial 
etiologies shows that PSI scores may not be an accurate indicator of severity of disease. More 
studies are needed to identify the best process of care for patients with CAP, including the potential 
benefits of routine respiratory viral panel testing and empiric antiviral therapy.
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Methods
Study Design 
This was a secondary data analysis of the Community-Acquired 
Pneumonia Organization (CAPO) international study database. 
This multinational database is coordinated by the University of 
Louisville School of Medicine, Department of Medicine, Division 
of Infectious Diseases. Investigators from 130 hospitals across 
30 countries perform data collection designed by the University 
of Louisville. Data is electronically transferred and validated by 
research associates at the University of Louisville [13].
Subjects
Patients were eligible for inclusion in analysis if they were 
hospitalized with CAP and a microbiological diagnosis of a viral 
or bacterial infection was established. Patients were enrolled 
from 2001 to 2017 and categorized into two groups: those 
with confirmed bacterial infection and those with confirmed 
viral infection. Patients without an identified bacterial or viral 
organism were excluded from the study. Additionally, patients 
with any coinfection were excluded.
Study Definitions
Community-acquired pneumonia (CAP):
A patient was defined as having CAP when the following 3 
criteria were met: 1) presence of a new pulmonary infiltrate on 
chest radiograph and/or chest computed tomography scan at the 
time of hospitalization, defined by a board-certified radiologist’s 
reading; 2) at least 1 of the following: a) new cough or increased 
cough or sputum production, b) fever >37.8°C (100.0°F) or 
hypothermia <35.6°C (96.0°F), c) changes in leukocyte count 
(leukocytosis: >11000 cells/μL; left shift: >10% band forms/mL; 
or leukopenia: <4000 cells/μL); and 3) no alternative diagnosis 
at the time of hospital discharge that justified the presence of 
criteria 1 and 2 [14].
Hospitalization with community-acquired bacterial 
pneumonia (CABP) vs. community-acquired viral 
pneumonia (CAVP): 
A microbiological diagnosis of CABP was based on the isolation 
of a bacterium from a respiratory sample, blood culture and/
or identification of a urinary antigen for Streptococcus or 
Legionella; microbiological diagnosis of CAVP was based on 




A patient was defined as having coinfection if more than one 
microorganism was identified. All patients with coinfections 
were excluded from analysis.
Measurements
Data was collected concerning patient demographics, physical 
examination findings, laboratory findings, radiological findings, 
severity of illness, and clinical outcomes and stratified according 
to the two study groups, CAVP and CABP.
Statistical Analysis
Descriptive statistics were performed, with frequencies with 
percentages as well as medians with interquartile ranges 
reported for categorical and continuous variables, respectively. 
Chi-squared tests and Mann-Whitney U-tests were performed 
to compare categorical and continuous variables.  P-values of 
less than 0.05 were considered statistically significant. R v 3.4.3 
was used for all analyses [15]. 
Results
Our study included 1913 patients. Of these, 286 (15.0%) had 
CAVP, while 1,627 (85.0%) had CABP. The most common 
organisms identified for patients CAVP and CABP depicted in 
Tables 1 and 2, respectively. 
1. Patient Demographics
Patients with CABP were older (63 [IQR: 31] vs. 48 [IQR: 28] 
years; P < 0.001) and were more frequently male (64% vs 
51%; P <0.001) than patients with CAVP. A higher proportion 
of co-morbidities, including chronic obstructive pulmonary 
disease (COPD), congestive heart failure (CHF), Human 
Immunodeficiency Virus (HIV), stroke, and neoplastic diseases 
were also more commonly found in patients with CABP in 
comparison to those with CAVP.  
2. Physical Examination Findings
Comparison between vitals measurements are shown in 
Table 3. While many variables were statistically significant, 
the differences between the CABP and CAVP groups were not 
considered clinically significant.
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Table 1 Most common pathogens isolated in CAVP
Pathogen n (%)
   Influenza H1N1 250 (87)
   Influenza H2N2 11 (4)
   Rhinovirus 8 (3)
   Respiratory Syncytial Viral (A,B) 5 (2)
   Parainfluenza Virus (1,2,3) 5 (2)
   Adenovirus 4 (1)
   Respiratory Syncytial Virus B 1 (0)
   Influenza B 1 (0)
   Coronavirus NL63 1 (0)
Pathogen n (%)
   Streptococcus pneumoniae 858 (53)
   Haemophilus influenzae 115 (7)
   MSSA 99 (6)
   Legionella spp. 95 (6)
   MRSA 79 (5)
   Pseudomonas aeruginosa 72 (4)
   Mycobacterium tuberculosis 61 (4)
   Mycoplasma pneumoniae 56 (3)
   Klebsiella pneumoniae 50 (3)
   Escherichia coli 35 (2)
   Moraxella catarrhalis 34 (2)
   Chlamydia pneumoniae 18 (1)
   Acinetobacter spp. 10 (1)
   Nontuberculous mycobacteria 8 (0)
   Proteus spp. 8 (0)
   Enterobacter spp. 7 (0)
   Streptococcus pyogenes 6 (0)
   Pseudomonas pseudomallei 4 (0)
   Other 12 (1)
Table 2 Most common pathogens isolated in CABP
3. Laboratory Findings
Comparison of laboratory values are shown in Table 3. Largest 
difference between the two groups was observed in the blood 
urea nitrogen (BUN), with bacterial pneumonia having a higher 
BUN value compared to that found in viral pneumonia (30 [IQR: 
32] vs. 22 [IQR: 21.5] mg/dL; P < 0.001). Serum procalcitonin 
was only enumerated for 18 (6%) patients with CAVP and 
118 (7%) patients with CABP; among those patients, serum 
procalcitonin was significantly higher for CABP compared to 
CAVP (0.73 [IQR: 4.39] vs. 0.22 [IQR: 0.94] µg/L; p = 0.026). 
Other differences were clinically or statistically non-significant.
4. Radiological Features
Radiological findings are shown in Table 3. On chest 
radiograph, patients with CAVP had more often diffuse bilateral 
infiltrate (3% vs 1%; P = 0.03) and unilateral diffuse infiltrate 
(5% vs 1%; P < 0.001).  Multilobar infiltrates were also seen 
more commonly, though statistically non-significant, in CAVP 
than CABP (58% vs. 53%, P = 0.095). 
5. Severity of Illness
Severity of disease on admission was characterized by frequency 
of pneumonia severity index (PSI) class IV or greater, need 
for ICU admission, altered mental status, need for ventilator 
support, and need for vasopressors, as shown in Table 4. There 
was a greater frequency of PSI ≥ class IV in CABP patients than 
CAVP patients (38% vs. 30%; P = 0.014). Patients with CAVP 
more frequently needed intensive care admission (33% vs. 17%; 
P < 0.001), ventilator support (33% vs. 18%; P <0.001), and 
vasopressors (20% vs. 9%; P <0.001). Altered mental status 
was observed to have equal frequency in both groups (15%; P 
= 0.928).
6. Patient outcomes 
Patient outcomes were characterized by time to clinical stability, 
hospital length of stay, in-hospital mortality, and 30-day 
mortality, as shown in Table 4. Times to clinical stability was 
not significantly different between CAVP and CABP groups (4 
[IQR: 6] vs. 5 [IQR: 5] days); P = 0.276). Lengths of stay were 8 
days in both groups. The percentage of in hospital mortality was 
significantly higher in patients suffering from CAVP compared 
to CABP (17% vs. 9%; P <0.001); however, mortality at 30 
days was not found to be significantly higher (24% vs. 21%; P 
= 0.345).
Discussion
Using the international CAPO database, we were able to 
retrospectively evaluate 1,913 patients admitted to the hospital 
for CAP to compare and contrast the clinical presentation, 
morbidity, and mortality of CAVP and CABP. Demographically, 
when compared to viral CAP, we found that bacterial etiologies 
are more commonly found in males and older patients. Bacterial 
pneumonia also is more frequent than viral pneumonia in 
patients with chronic obstructive pulmonary disease, congestive 
heart failure, human immunodeficiency virus, stroke, neoplastic 
disease, and those on home oxygen. Physical exam characteristics 
were found to be clinically non-significant between both groups. 
Furthermore, the blood urea nitrogen level, a nonspecific 
marker of plasma volume status, and frequency of PSI scores 
≥4 were found to be higher in patients with CABP. However, 
the overlapping similarity in findings when comparing physical 
exam, laboratory data, and radiographic findings is in line with 
the extreme difficulty in diagnosing between bacterial vs. viral 
pneumonias. This is important to address as CAVP patients were 
observed to have a greater frequency of overall disease severity 
when comparing the frequency of need for ICU admission, 
ventilator support, vasopressor therapy, and mortality.
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Table 3 Patient demographics, physical examination findings, laboratory 
findings, and radiological findings




Severity of Disease on 
Admission P-value
Pneumonia severity index 
risk class IV or V 620 (38) 87 (30) 0.014
Need for intensive care 282 (17) 94 (33) <0.001
Altered mental status 243 (15) 41 (15) 0.928
Need for ventilatory 
support 131 (18) 91 (33) <0.001
Need for vasopressors 65 (9) 55 (20) <0.001
Outcomes P-value
Time to Clinical Stability, 
Median (IQR) 5 (5) 4 (6) 0.276
Length of Stay, Median 
(IQR) 8 (9) 8 (11) 0.195
In-Hospital Mortality, n (%) 148 (9) 50 (17) <0.001
Mortality at 30 Days, n (%) 248 (21) 47 (24) 0.345
Frequency (%)
Variable CABP CAVP
Total study population, n 1627 286
Demographics P-value
Male sex, n (%) 1033 (64) 145 (51) <0.001
Age, Median(IQR)* 63 (31) 48 (28) <0.001
Chronic obstructive pulmonary 
disease
364 (22) 41 (14) 0.002
Diabetes mellitus 282 (17) 43 (15) 0.393
Current smoker 275 (17) 58 (20) 0.176
Congestive heart failure 227 (14) 27 (9) 0.038
HIV disease 200 (12) 8 (3) <0.001
Stroke 162 (10) 8 (3) <0.001
Neoplastic disease 160 (10) 12 (4) 0.002
Renal disease 156 (10) 21 (7) 0.268
Chronic renal failure 130 (8) 22 (8) >0.999
Home oxygen 30 (4) 4 (1) 0.032
Physical Examination Findings P-
value
Systolic blood pressure (mmHg) 119 (33) 120 (34) 0.01
Heart rate (Beats/Minute) 104 (31) 100 (28) 0.026
Diastolic blood pressure (mmHg) 70 (20) 72.5 (23) <0.001
Temperature (Degrees Celsius) 37.8 (1.9) 37.8 (1.7) 0.073
Respiratory rate (Breaths/Minute) 24 (8) 26 (12) <0.001
Laboratory Findings P-
value
Serum sodium (mEq/L) 136 (7.0) 136 (6.0) 0.034





Hematocrit (percent) 38 (7.8) 39 (6.5) <0.001
Blood urea nitrogen (mg/dL) 30 (32.0) 22 (21.5) <0.001
Serum bicarbonate (mEq/L) 23.8 (6.2) 23 (6.0) 0.492







Diffuse Bilateral, n (%) 20 (1) 9 (3) 0.03
Diffuse Unilateral, n (%) 11 (1) 15 (5) <0.001





Table 4 Severity of illness and clinical outcomes
Our findings are both supported and refuted by currently 
established literature, reiterating the ambiguity between and 
difficulty in distinguishing the clinical presentation and severity 
of illness of bacterial vs. viral etiologies of CAP. For example, 
Johnstone found that viral pneumonias, in comparison to non-
viral causes of pneumonia, were found to be more prevalent in 
older and frailer patients [16]. Other studies have identified a 
similar age difference between the two groups [6,17]. This is 
contrary to our finding that CABP patients are older than CAVP 
patients. Also, patients with COPD, CHF, and cerebrovascular 
disease were also found to be more commonly affected by viral 
CAP than bacterial CAP [17]. Similar to our findings, on the 
other hand, malignancy was observed to be more commonly 
found in patients with bacterial etiologies than viral [17]. HIV 
was also observed to be more common in bacterial CAP than 
viral CAP [18]. Despite these findings, it is important to also 
note that multiple studies found no significant difference in age 
or comorbidities between bacterial and viral etiologies of CAP 
[19-22].
Medical literature also supports our findings that physical exam 
and laboratory values are often unable to definitively distinguish 
between bacterial vs. viral pneumonias [17]. We did not find 
drastic differences between the two groups when comparing 
physical exam findings. These minor, yet significant differences 
were seen when comparing respiratory rate, blood pressure, and 
degree of tachycardia. We found higher BUN levels in patients 
suffering from CABP compared to CAVP. Higher levels of BUN 
have been shown to be associated with increased mortality 
in patients with CAP [23,24], however there were no studies 
found comparing BUN levels in CAVP vs. CABP. While we 
observed a significant difference in serum procalcitonin, the 
large proportion of patients missing those values should cause 
caution when interpreting these results. Though we observed 
significant, yet minor differences in serum glucose, hematocrit, 
and bicarbonate values between CABP and CAVP, Johnstone 
went on to state, “it seems unlikely that any constellation of 
symptoms, signs, and routine laboratory findings will ever 
reliably differentiate between the presence or absence of a 
virus.16 Furthermore, though there are several studies showing 
the clinical and laboratory findings of pure bacterial, pure 
viral, and combined bacterial-viral CAP infections [16,20,25], 
diagnosing and differentiating purely viral from bacterial CAP 
remains a problem as the etiology for a significant proportion 
of CAP remains unknown. It is estimated that 40-60% of CAP 
remains unidentified [3,26,27]. Caglayan states that bacterial 
CAP infections resemble combined bacterial-viral CAP in terms 
of mean age, immune status, leukocyte count, C-reactive protein 
(CRP) values, hospitalization duration and CURB-65 score [25].
We also evaluated disease severity in the setting of purely viral 
vs. purely bacterial CAP. CABP more frequently had PSI ≥ class 
IV, however CAVP significantly showed higher frequencies of 
ICU admission, intubation, vasopressor support, and in hospital 
mortality. Though it has been previously demonstrated that PSI 
≥ class IV indicates increased disease severity and is strongly 
associated with ICU admission [28,29], our results show that 
PSI scores cannot be used to accurately prognosticate viral CAPs. 
Furthermore, literature suggests that PSI often underestimates 
the risk of patients with Influenza A H1N1 pneumonia [30,31] 
and neither PSI nor CURB-65 scores can be used to predict 
ICU admission or need for mechanical ventilation in influenza 
patients31. The CDC recommends early antiviral therapy for 
patients who are suspected of suffering from influenza [32]. 
There exist limitations to our study. First, this was a retrospective 
study. Secondly, while the multicenter and international nature 
of the study increases the strength and generalizability of 
results, the data collection and other differences in process of 
care provide an unmeasurable confounding element that may 
have significant impact on data collection. Also, a large portion 
of patients included were afflicted by the H1N1 pandemic in 
2009, that may explain the increased mortality for CAVP. 
Patients affected by H1N1 are observed to be younger in age 
and with fewer comorbidities [33]. Furthermore, pathogens 
identified from respiratory samples may represent colonization 
or active infection. 
 
In conclusion, our study confirms the extreme difficulty 
differentiating CABP from CAVP using demographics, physical 
exam, or x-ray findings. We found no major clinical or laboratory 
findings distinguishing CABP from CAVP. The increased 
severity of illness of CAVP compared to bacterial etiologies 
shows that PSI scores may not be an accurate indicator of 
severity of disease. More studies are needed to identify the best 
process of care for patients with CAP, including the potential 
benefits of routine respiratory viral panel testing and empiric 
antiviral therapy.
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